Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COV-BOOST: Evaluating COVID-19 Vaccination Boosters
ISRCTN73765130Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
01
Overview
Phase 2, randomised, double-blind trial of ChAdOx1 nCoV-19, tozinameran, elasomeran, NVX-CoV2373, VLA2001 and 5 more in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Serum anti-spike IgG at 28 days, Solicited adverse events and 2 more. Started Jun 2021; status: completed.
02
Drugs
ChAdOx1 nCoV-19tozinameranelasomeranNVX-CoV2373VLA2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN73765130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN73765130.